Abstract
Introduction: DISCOVER-1/2 psoriatic arthritis (PsA) trials demonstrated significant efficacy with guselkumab (GUS) vs placebo (PBO), with good tolerability, at week (W) 24. This analysis describes pooled safety through 1-year of GUS treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
